Klotho Neurosciences Inc
KLTO
Company Profile
Business description
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Contact
13576 Walnut Street
Suite A
OmahaNE68144
USAT: +1 833 931-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,524.80 | 55.10 | -0.64% |
| CAC 40 | 7,886.69 | 33.22 | 0.42% |
| DAX 40 | 23,767.43 | 71.84 | 0.30% |
| Dow JONES (US) | 42,654.74 | 331.99 | 0.78% |
| FTSE 100 | 8,684.56 | 50.81 | 0.59% |
| HKSE | 23,311.10 | 33.95 | -0.15% |
| NASDAQ | 19,211.10 | 98.78 | 0.52% |
| Nikkei 225 | 37,498.63 | 255.09 | -0.68% |
| NZX 50 Index | 12,629.07 | 157.72 | -1.23% |
| S&P 500 | 5,958.38 | 41.45 | 0.70% |
| S&P/ASX 200 | 8,295.10 | 48.60 | -0.58% |
| SSE Composite Index | 3,367.12 | 0.35 | -0.01% |